1. Home
  2. ZGN vs MIRM Comparison

ZGN vs MIRM Comparison

Compare ZGN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ermenegildo Zegna N.V.

ZGN

Ermenegildo Zegna N.V.

HOLD

Current Price

$10.48

Market Cap

2.7B

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$65.05

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZGN
MIRM
Founded
1910
2018
Country
Italy
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.7B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
ZGN
MIRM
Price
$10.48
$65.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
11
Target Price
$10.98
$87.55
AVG Volume (30 Days)
581.9K
560.0K
Earning Date
09-05-2025
11-04-2025
Dividend Yield
1.35%
N/A
EPS Growth
N/A
N/A
EPS
0.43
N/A
Revenue
$2,248,050,499.00
$471,794,000.00
Revenue This Year
N/A
$53.78
Revenue Next Year
$5.08
$19.91
P/E Ratio
$24.10
N/A
Revenue Growth
N/A
53.66
52 Week Low
$6.05
$36.88
52 Week High
$11.00
$78.55

Technical Indicators

Market Signals
Indicator
ZGN
MIRM
Relative Strength Index (RSI) 54.73 36.47
Support Level $10.12 $63.66
Resistance Level $11.00 $66.77
Average True Range (ATR) 0.29 2.99
MACD -0.01 -0.66
Stochastic Oscillator 54.64 13.68

Price Performance

Historical Comparison
ZGN
MIRM

About ZGN Ermenegildo Zegna N.V.

Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: